XOMA Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential… Read more
XOMA Corp (XOMA) - Net Assets
Latest net assets as of September 2025: $107.96 Million USD
Based on the latest financial reports, XOMA Corp (XOMA) has net assets worth $107.96 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($263.15 Million) and total liabilities ($155.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $107.96 Million |
| % of Total Assets | 41.02% |
| Annual Growth Rate | 4.81% |
| 5-Year Change | -5.21% |
| 10-Year Change | N/A |
| Growth Volatility | 2359.98 |
XOMA Corp - Net Assets Trend (1985–2024)
This chart illustrates how XOMA Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XOMA Corp (1985–2024)
The table below shows the annual net assets of XOMA Corp from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $81.92 Million | -7.66% |
| 2023-12-31 | $88.72 Million | -28.46% |
| 2022-12-31 | $124.01 Million | -12.59% |
| 2021-12-31 | $141.88 Million | +64.16% |
| 2020-12-31 | $86.42 Million | +96.47% |
| 2019-12-31 | $43.99 Million | +134.17% |
| 2018-12-31 | $18.79 Million | +224.66% |
| 2017-12-31 | $5.79 Million | +112.26% |
| 2016-12-31 | $-47.21 Million | -1944.61% |
| 2015-12-31 | $-2.31 Million | -174.51% |
| 2014-12-31 | $3.10 Million | +177.73% |
| 2013-12-31 | $-3.99 Million | -118.57% |
| 2012-12-31 | $21.47 Million | +43.01% |
| 2011-12-31 | $15.01 Million | -36.37% |
| 2010-12-31 | $23.59 Million | +34.61% |
| 2009-12-31 | $17.53 Million | +155.81% |
| 2008-12-31 | $-31.40 Million | -9974.53% |
| 2007-12-31 | $318.00K | +100.83% |
| 2006-12-31 | $-38.17 Million | -84.67% |
| 2005-12-31 | $-20.67 Million | +16.01% |
| 2004-12-31 | $-24.61 Million | -151.04% |
| 2003-12-31 | $48.21 Million | +524.23% |
| 2002-12-31 | $-11.37 Million | -183.45% |
| 2001-12-31 | $13.62 Million | +258.54% |
| 2000-12-31 | $-8.59 Million | +49.17% |
| 1999-12-31 | $-16.90 Million | -8550.00% |
| 1998-12-31 | $200.00K | -99.36% |
| 1997-12-31 | $31.20 Million | -10.09% |
| 1996-12-31 | $34.70 Million | +29.48% |
| 1995-12-31 | $26.80 Million | -38.39% |
| 1994-12-31 | $43.50 Million | -44.52% |
| 1993-12-31 | $78.40 Million | -11.41% |
| 1992-12-31 | $88.50 Million | -34.20% |
| 1991-12-31 | $134.50 Million | +409.47% |
| 1990-12-31 | $26.40 Million | -2.58% |
| 1989-12-31 | $27.10 Million | -9.06% |
| 1988-12-31 | $29.80 Million | -22.60% |
| 1987-12-31 | $38.50 Million | +220.83% |
| 1986-12-31 | $12.00 Million | -8.40% |
| 1985-12-31 | $13.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XOMA Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 122105700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $90.00K | 0.11% |
| Other Comprehensive Income | $73.00K | 0.09% |
| Other Components | $1.32 Billion | 1609.86% |
| Total Equity | $81.92 Million | 100.00% |
XOMA Corp Competitors by Market Cap
The table below lists competitors of XOMA Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viel et Cie.
LSE:0HZW
|
$255.81 Million |
|
High Templar Tech Limited
LSE:0A2T
|
$255.82 Million |
|
LAY-OUT Planning Consultants Co. Ltd.
SHE:300989
|
$255.83 Million |
|
BELLSYSTEM24 HLDGS O.N.
F:B24
|
$255.84 Million |
|
XiAn Typical Industries Co Ltd
SHG:600302
|
$255.65 Million |
|
Neosem Inc
KQ:253590
|
$255.36 Million |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
$255.32 Million |
|
Piovan S.p.A
F:PV0
|
$255.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XOMA Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 88,721,000 to 81,921,000, a change of -6,800,000 (-7.7%).
- Net loss of 13,821,000 reduced equity.
- Dividend payments of 5,472,000 reduced retained earnings.
- Share repurchases of 13,000 reduced equity.
- Other comprehensive income increased equity by 1,441,000.
- Other factors increased equity by 11,065,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.82 Million | -16.87% |
| Dividends Paid | $5.47 Million | -6.68% |
| Share Repurchases | $13.00K | -0.02% |
| Other Comprehensive Income | $1.44 Million | +1.76% |
| Other Changes | $11.06 Million | +13.51% |
| Total Change | $- | -7.66% |
Book Value vs Market Value Analysis
This analysis compares XOMA Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.06x to 3.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $466.69 | $27.00 | x |
| 1986-12-31 | $490.28 | $27.00 | x |
| 1987-12-31 | $1323.93 | $27.00 | x |
| 1988-12-31 | $834.41 | $27.00 | x |
| 1989-12-31 | $615.13 | $27.00 | x |
| 1990-12-31 | $561.42 | $27.00 | x |
| 1991-12-31 | $2082.20 | $27.00 | x |
| 1992-12-31 | $1240.12 | $27.00 | x |
| 1993-12-31 | $1097.09 | $27.00 | x |
| 1994-12-31 | $595.92 | $27.00 | x |
| 1995-12-31 | $339.66 | $27.00 | x |
| 1996-12-31 | $320.38 | $27.00 | x |
| 1997-12-31 | $236.69 | $27.00 | x |
| 1998-12-31 | $1.40 | $27.00 | x |
| 1999-12-31 | $-96.20 | $27.00 | x |
| 2000-12-31 | $-39.82 | $27.00 | x |
| 2001-12-31 | $59.94 | $27.00 | x |
| 2002-12-31 | $-48.46 | $27.00 | x |
| 2003-12-31 | $192.68 | $27.00 | x |
| 2004-12-31 | $-87.00 | $27.00 | x |
| 2005-12-31 | $-68.85 | $27.00 | x |
| 2006-12-31 | $-119.34 | $27.00 | x |
| 2007-12-31 | $0.75 | $27.00 | x |
| 2008-12-31 | $-70.87 | $27.00 | x |
| 2009-12-31 | $30.98 | $27.00 | x |
| 2010-12-31 | $25.35 | $27.00 | x |
| 2011-12-31 | $9.50 | $27.00 | x |
| 2012-12-31 | $6.64 | $27.00 | x |
| 2013-12-31 | $-0.92 | $27.00 | x |
| 2014-12-31 | $0.54 | $27.00 | x |
| 2015-12-31 | $-0.39 | $27.00 | x |
| 2016-12-31 | $-7.84 | $27.00 | x |
| 2017-12-31 | $0.73 | $27.00 | x |
| 2018-12-31 | $2.24 | $27.00 | x |
| 2019-12-31 | $5.02 | $27.00 | x |
| 2020-12-31 | $7.51 | $27.00 | x |
| 2021-12-31 | $11.64 | $27.00 | x |
| 2022-12-31 | $10.87 | $27.00 | x |
| 2023-12-31 | $7.73 | $27.00 | x |
| 2024-12-31 | $7.00 | $27.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XOMA Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.52%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 2.70x
- Recent ROE (-16.87%) is above the historical average (-770.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -36.64% | -65.75% | 0.49x | 1.14x | $-6.11 Million |
| 1986 | -389.17% | -46700.00% | 0.00x | 3.95x | $-47.90 Million |
| 1987 | -12.47% | -62.34% | 0.12x | 1.73x | $-8.65 Million |
| 1988 | -40.27% | -240.00% | 0.09x | 1.85x | $-14.98 Million |
| 1989 | -69.74% | -181.73% | 0.09x | 4.08x | $-21.61 Million |
| 1990 | -89.77% | -115.61% | 0.21x | 3.67x | $-26.34 Million |
| 1991 | -25.50% | -200.58% | 0.11x | 1.15x | $-47.75 Million |
| 1992 | -53.22% | -923.53% | 0.05x | 1.24x | $-55.95 Million |
| 1993 | -39.92% | -5216.67% | 0.01x | 1.20x | $-39.14 Million |
| 1994 | -79.54% | -2035.29% | 0.03x | 1.43x | $-38.95 Million |
| 1995 | -83.96% | -1875.00% | 0.03x | 1.53x | $-25.18 Million |
| 1996 | -83.86% | -808.33% | 0.06x | 1.66x | $-32.57 Million |
| 1997 | -50.64% | -85.87% | 0.28x | 2.08x | $-18.92 Million |
| 1998 | -23600.00% | -749.21% | 0.17x | 186.50x | $-47.22 Million |
| 1999 | 0.00% | -1908.33% | 0.08x | 0.00x | $-44.11 Million |
| 2000 | 0.00% | -441.69% | 0.15x | 0.00x | $-28.55 Million |
| 2001 | -205.89% | -162.28% | 0.20x | 6.32x | $-29.40 Million |
| 2002 | 0.00% | -111.01% | 0.42x | 0.00x | $-32.11 Million |
| 2003 | -121.65% | -240.26% | 0.21x | 2.47x | $-63.47 Million |
| 2004 | 0.00% | -2153.94% | 0.08x | 0.00x | $-76.48 Million |
| 2005 | 0.00% | 14.89% | 0.26x | 0.00x | $4.85 Million |
| 2006 | 0.00% | -175.74% | 0.32x | 0.00x | $-48.02 Million |
| 2007 | -3876.10% | -14.63% | 0.99x | 266.71x | $-12.36 Million |
| 2008 | 0.00% | -66.55% | 1.01x | 0.00x | $-42.10 Million |
| 2009 | 3.14% | 0.56% | 1.86x | 3.01x | $-1.20 Million |
| 2010 | -291.45% | -204.38% | 0.45x | 3.15x | $-71.12 Million |
| 2011 | -218.13% | -56.26% | 0.75x | 5.20x | $-34.24 Million |
| 2012 | -331.04% | -210.36% | 0.32x | 4.92x | $-73.21 Million |
| 2013 | 0.00% | -349.94% | 0.26x | 0.00x | $-123.66 Million |
| 2014 | -1235.91% | -203.02% | 0.21x | 28.92x | $-38.61 Million |
| 2015 | 0.00% | -37.16% | 0.74x | 0.00x | $-20.38 Million |
| 2016 | 0.00% | -962.08% | 0.19x | 0.00x | $-48.81 Million |
| 2017 | 252.26% | 27.70% | 1.17x | 7.77x | $14.02 Million |
| 2018 | -71.03% | -251.80% | 0.08x | 3.40x | $-15.22 Million |
| 2019 | -4.51% | -10.79% | 0.19x | 2.18x | $-6.38 Million |
| 2020 | 15.39% | 45.25% | 0.23x | 1.45x | $4.66 Million |
| 2021 | 11.14% | 41.40% | 0.23x | 1.17x | $1.61 Million |
| 2022 | -13.79% | -283.79% | 0.04x | 1.13x | $-29.51 Million |
| 2023 | -46.02% | -858.15% | 0.02x | 2.64x | $-49.70 Million |
| 2024 | -16.87% | -48.52% | 0.13x | 2.70x | $-22.01 Million |
Industry Comparison
This section compares XOMA Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XOMA Corp (XOMA) | $107.96 Million | -36.64% | 1.44x | $255.80 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |